Abstracts tagged "psoriasis"

Abstract Number: 1614 • 2018 ACR/ARHP Annual Meeting
Prevalence of Sonographic Enthesitis in Patients with Psoriasis without Arthritis and Its Association Risk Factors of Psoriatic Arthritis
Anwar Albasri¹, Justine Y. Ye², Cheryl F. Rosen³, Vinod Chandran², Dafna D Gladman⁴ and Lihi Eder⁵, ¹Rheumatology, University of Toronto, Toronto, ON, Canada, ²Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ³University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁴Department of Medicine, Toronto Psoriatic Arthritis Research Program, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁵Women's College Research Institute, University of Toronto, Women's College Hospital, Toronto, ON, Canada
Background/Purpose: Enthesitis is one of the hallmarks of psoriatic arthritis (PsA) and may be the initial site of musculoskeletal inflammation. Enthesitis affects up to 50…
Abstract Number: 2447 • 2018 ACR/ARHP Annual Meeting
Liver Enzyme Abnormalities after Tofacitinib Treatment in Patients with Hepatic Steatosis from the Rheumatoid Arthritis, Psoriatic Arthritis, and Psoriasis Clinical Programs
Enrique R Soriano¹, Hugo Madariaga², Oswaldo Castañeda³, Gustavo Citera⁴, Emilce E Schneeberger⁴, Mario H Cardiel⁵, Thijs Hendrikx⁶, Daniela Graham⁷, Harry Shi⁶ and Dario Ponce de Leon⁸, ¹Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ²Clínica del Sur, Arequipa, Peru, ³Clínica Anglo Americana, Lima, Peru, ⁴Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, ⁵Centro de Investigación Clínica de Morelia, Morelia, Mexico, ⁶Pfizer Inc, Collegeville, PA, ⁷Pfizer Inc, Groton, CT, ⁸Pfizer Inc, Lima, Peru
Background/Purpose: Non-alcoholic fatty liver disease, characterized by hepatic steatosis (HS), is a very common form of chronic liver disease in many countries. Limited data are…
Abstract Number: 2567 • 2018 ACR/ARHP Annual Meeting
Clinically Meaningful Improvement in Skin and Nail Psoriasis in Bio-Naïve Active Psoriatic Arthritis Patients Treated with Intravenous Golimumab: Results through Week 24 from a Phase 3 Study
M. Elaine Husni¹, Philip J. Mease², Soumya D Chakravarty³, Shelly Kafka⁴, Diane D. Harrison⁵, Dennis Parenti⁴, Lilianne Kim⁵, Kim Hung Lo⁵, Elizabeth C Hsia⁶ and Arthur Kavanaugh⁷, ¹Cleveland Clinic, Cleveland, OH, ²Swedish Medical Center & U of Wash School of Medicine, Seattle, WA, ³Janssen Scientific Affairs, LLC/Drexel U School of Medicine, Horsham/Phila, PA, ⁴Janssen Scientific Affairs, LLC, Horsham, PA, ⁵Janssen Research & Development, LLC, Spring House, PA, ⁶Janssen Research & Development, LLC/University of Pennsylvania, Spring House/Philadelphia, PA, ⁷UCSD, San Diego, CA
Background/Purpose: GO-VIBRANT was a Phase 3 trial of intravenous (IV) golimumab (GLM) in adult patients (pts) w/active psoriatic arthritis (PsA). To evaluate improvement in skin,…
Abstract Number: 2904 • 2018 ACR/ARHP Annual Meeting
Serum, Cellular and Imaging Markers of Arthritis in Psoriasis Patients and Healthy Controls
Ralf G. Thiele¹, Yahui Grace Chiu², Nelson Huertas³, Dongge Li⁴, Changyong Feng⁵, Sharon Moorehead⁶, Cristy Bell⁷ and Christopher T. Ritchlin⁸, ¹Division of Rheumatology, University of Rochester Medical Center, Rochester, NY, ²Wilmot Cancer Center, University of Rochester Medical Center, Rochester, NY, ³Department of Medicine, Division of Allergy, Immunology and Rheumatology, School of Medicine and Dentistry, University of Rochester, Rochester, New York, USA, Rochester, NY, ⁴Allergy, Immunology and Rheumatology, Division of Allergy/Immunology and Rheumatology and Center for Musculoskeletal Research, School of Medicine and Dentistry, University of Rochester Medical School, Rochester, New York, USA, Rochester, NY, ⁵Statistics, University of Rochester, Rochester, NY, ⁶Allergy, Immunology & Rheumatology, University of Rochester, Rochester, NY, ⁷Allergy, Immunology and Rheumatology, University of Rochester, Rochester, NY, ⁸Division of Allergy/Immunology and Rheumatology and Center for Musculoskeletal Research, School of Medicine and Dentistry, University of Rochester Medical School, Rochester, New York, USA, Rochester, NY
Background/Purpose: The events that underlie the transition from psoriasis (Ps) to psoriatic arthritis (PsA) are not well understood, although up to 30% of Ps patients…
Abstract Number: 640 • 2018 ACR/ARHP Annual Meeting
Increasing Rates of Arthroplasty for Psoriatic Arthritis in the United Kingdom between 1995 and 2010
Ryan Lewinson¹, Isabelle Vallerand², Jeremy LaMothe³, Laurie Parsons¹, Alexandra Frolkis⁴, Mark Lowerison², Scott Patten² and Cheryl Barnabe^2,5, ¹Dermatology, University of Calgary, Calgary, AB, Canada, ²Department of Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ³Orthopaedic Surgery, University of Calgary, Calgary, AB, Canada, ⁴Internal Medicine, University of Calgary, Calgary, AB, Canada, ⁵Division of Rheumatology, University of Calgary, Calgary, AB, Canada
Background/Purpose: Arthroplasty requirements among patients with psoriatic arthritis (PsA) are not well known. This information is of importance to clinical and policy stakeholders for health…
Abstract Number: 652 • 2018 ACR/ARHP Annual Meeting
Disease Interception in Psoriasis Patients with Subclinical Joint Inflammation By Interleukin 17 Inhibition with Secukinumab – Data from a Prospective Open Label Study
Eleni Kampylafka¹, Isabelle Oliveira¹, Christina Linz², Veronika Lerchen¹, Matthias Englbrecht¹, David Simon³, Michael Sticherling⁴, Juergen Rech⁵, Arnd Kleyer³, Georg Schett⁶ and Axel J. Hueber³, ¹Department of Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg, Erlangen, Germany, ²Department of Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg, e, Germany, ³Department of Internal Medicine 3—Rheumatology and Immunology, Friedrich-Alexander-University Erlangen–Nürnberg (FAU), Universitätsklinikum Erlangen, Erlangen, Germany, Erlangen, Germany, ⁴Department of Dermatology, Friedrich-Alexander-University Erlangen-Nürnberg, Erlangen, Germany, ⁵Universitätsklinikum Erlangen, Erlangen, Germany, ⁶Department of Internal Medicine 3, Rheumatology and Immunology, Universitätsklinikum Erlangen, Erlangen, Germany
Background/Purpose: Musculoskeletal changes precede the onset of psoriatic arthritis (PsA). A subset of psoriasis patients is characterized by arthralgia as well as inflammatory changes in…
Abstract Number: 679 • 2018 ACR/ARHP Annual Meeting
Ultrasonographic Research of the Relationship between Nail Disorders and Peripheral Arthritis or Enthesitis in Patients with Psoriasis and Psoriatic Arthritis
Tadashi Okano¹, Kentaro Inui², Koji Mandai³, Yutaro Yamada⁴, Tatsuya Koike⁵ and Hiroaki Nakamura², ¹Orthopedic Surgery, Osaka City University Graduate School of Medicine, Osaka, Japan, ²Orthopaedic Surgery, Osaka City University Graduate School of Medicine, Osaka, Japan, ³Orthopaedic surgery, Osaka City University Graduate School of Medicine, Osaka, Japan, ⁴Orthopedic surgery, Yodogawa Christian Hospital, Osaka, Japan, ⁵Center for Senile Degenerative Disorders, Osaka City University Graduate School of Medicine, Osaka, Japan
Background/Purpose: Although skin lesion is the most typical findings in patients with psoriasis (PsO), nail psoriasis is also one of the important clinical manifestation. Moreover,…
Abstract Number: 16L • 2017 ACR/ARHP Annual Meeting
Incidence of Thromboembolic Events in the Tofacitinib Rheumatoid Arthritis, Psoriasis, Psoriatic Arthritis and Ulcerative Colitis Development Programs
Philip J Mease¹, Joel Kremer², Stanley Cohen³, Jeffrey R Curtis⁴, Christina Charles-Schoeman⁵, Edward V Loftus⁶, Jeffrey D Greenberg⁷, Niki Palmetto⁸, Keith S Kanik⁹, Daniela Graham⁹, Cunshan Wang⁹, Pinaki Biswas⁸, Gary Chan¹⁰, Ryan DeMasi¹⁰, Hernan Valdez⁸, Thijs Hendrikx¹⁰ and Thomas V Jones¹⁰, ¹Swedish Medical Center and University of Washington, Seattle, WA, ²Medicine, Albany Medical College and the Center for Rheumatology, Albany, NY, ³Metroplex Clinical Research Center, Dallas, TX, ⁴University of Alabama, Birmingham, AL, ⁵University of California, Los Angeles, CA, ⁶Mayo Clinic, Rochester, MN, ⁷Corrona, LLC, Southborough, MA, ⁸Pfizer Inc, New York, NY, ⁹Pfizer Inc, Groton, CT, ¹⁰Pfizer Inc, Collegeville, PA

Background/Purpose: Tofacitinib is an oral Janus kinase (JAK) inhibitor that preferentially inhibits signaling by JAK3 and JAK1, with functional selectivity over JAK2. Potential increased risk…
Abstract Number: 1555 • 2017 ACR/ARHP Annual Meeting
Treatment Changes By Joint Activity and Skin Severity in Patients with Comorbid Psa and Pso
Philip J Mease¹, Carol J. Etzel², Jeffrey Lisse³, April W Armstrong⁴, William J Huster³, Sabrina Rebello², Rhiannon Dodge², Talia M Muram³, Sarah Al Sawah³, Mwangi J Murage³, Jeffrey D Greenberg² and William Malatestinic³, ¹Swedish Medical Center and University of Washington, Seattle, WA, ²Corrona, LLC, Southborough, MA, ³Eli Lilly and Company, Indianapolis, IN, ⁴Keck School of Medicine, University of Southern California, Los Angeles, CA
Background/Purpose: Treatment of both joint and skin symptoms is important for overall disease management of patients with psoriatic arthritis and comorbid psoriasis1,2. The objective of…
Abstract Number: 1557 • 2017 ACR/ARHP Annual Meeting
Treatment Patterns in Psoriatic Arthritis: Experience from a Real-World Setting
Martin Brom¹, Sebastian Moyano¹, Florencia Beatriz Mollerach², Luciano Fernando Lo Giudice³, Maria Laura Acosta Felquer¹, Marina Scolnik⁴, Santiago Ruta⁴ and Enrique R Soriano⁵, ¹Rheumatology Unit, Internal Medicine Service, Hospital Italiano de Buenos Aires, Instituto Universitario Hospital Italiano de Buenos Aires, and Fundacion PM Catoggio, Buenos Aires, Argentina, ²Rheumatology Unit, Internal Medicine Service, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ³Rheumatology section, Internal Medicine Unit, Hospital Italiano de Buenos Aires and Fundacion PM Catoggio, CABA, Argentina, ⁴Rheumatology Unit, Internal Medicine Service, Hospital Italiano de Buenos Aires, CABA, Argentina, ⁵Argentina, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina
Background/Purpose: Both EULAR (European League Against Rheumatism) and GRAPPA (Group for Research and Assessment of Psoriasis and Psoriatic Arthritis) recently published treatment guidelines for Psoriatic…
Abstract Number: 2309 • 2017 ACR/ARHP Annual Meeting
Risk Factors for Arthritis and the Development of Comorbid Cardiovascular and Metabolic Disease in Children with Psoriasis
Cynthia K. Manos^1,2, Rui Xiao³, Timothy G. Brandon¹, Alexis Ogdie⁴ and Pamela F. Weiss^5,6, ¹Rheumatology, Children's Hospital of Philadelphia, Philadelphia, PA, ²Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, Philadelphia, PA, ³Department of Pediatrics, Division of Biostatistics, Children's Hospital of Philadelphia, Philadelphia, PA, ⁴Rheumatology, Hospital of the University of Pennsylvania, Philadelphia, PA, ⁵Division of Rheumatology, Center for Pediatric Clincial Effectiveness, Children's Hospital of Philadelphia, Philadelphia, PA, ⁶Department of Pediatrics, Perelman School of Medicine, Philadelphia, PA
Background/Purpose: Relatively little is known about the epidemiology of juvenile psoriatic arthritis (PsA), including risk factors for development of PsA among children with psoriasis. It…
Abstract Number: 2481 • 2017 ACR/ARHP Annual Meeting
Long-Term Safety of Adalimumab (HUMIRA) in Adult Patients from Global Clinical Trials across Multiple Indications: An Updated Analysis in 29,987 Patients Representing 56,951 Patient-Years
Gerd R. Burmester¹, Remo Panaccione², Kenneth B. Gordon³, James T. Rosenbaum⁴, Dilek Arikan⁵, Winnie L. Lau⁵ and Rita Tarzynski-Potempa⁵, ¹Charité - University Medicine Berlin, Berlin, Germany, ²University of Calgary, Calgary, AB, Canada, ³Medical College of Wisconsin, Milwaukee, WI, ⁴Ophthalmology, Oregon Health & Science University and Legacy Devers Eye Institute, Portland, OR, ⁵AbbVie Inc., North Chicago, IL
Background/Purpose: Adalimumab is an anti–tumor necrosis factor-α (TNF-α) agent indicated for the treatment of immune-mediated diseases. The long-term safety of adalimumab was previously reported in…
Abstract Number: 2529 • 2017 ACR/ARHP Annual Meeting
Appraisal of the Contest Questionnaire in the Screening for Psoriatic Arthritis
Amir Haddad¹, Joy Feld^1,2, Lihi Eder³, Idit Lavi⁴, Oxana Zlazhover⁵ and Devy Zisman^1,6, ¹Rheumatology Unit Carmel Medical Center, Haifa, Israel, ²Rheumatology Unit, Carmel Medical Center, Haifa, Israel, ³Women's College Research Institute, Women's College Hospital, Toronto, ON, Canada, ⁴Epidemiology Unit Carmel Medical Center, Haifa, Israel, ⁵Bnei Zion Medical Center, Haifa, Israel, ⁶The Ruth and Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel
Background/Purpose: Early diagnosis of psoriatic arthritis (PsA) is critical to prevent poor outcome. Several validated screening questionnaires have been developed to identify PsA patients in…
Abstract Number: 2531 • 2017 ACR/ARHP Annual Meeting
Utilization of the Psoriasis Epidemiology Screening Tool to Identify Signs and Symptoms of Early Psoriatic Arthritis Among Those with Psoriasis: Analysis from the Corrona Psoriasis Registry
Philip J Mease¹, Jacqueline B. Palmer², Mark Lebwohl³, Chitra Karki⁴, George W. Reed⁵, Carol J. Etzel⁶, Jeffrey D. Greenberg⁷ and Philip S. Helliwell⁸, ¹Swedish Medical Center and University of Washington, Seattle, WA, ²Novartis Pharmaceuticals Corporation, East Hanover, NJ, ³Icahn School of Medicine at Mount Sinai, New York, NY, ⁴Corrona, LLC, Southborough, MA, ⁵University of Massachusetts Medical School, Worcester, MA, ⁶The University of Texas MD Anderson Cancer Center, Houston, TX, ⁷New York University School of Medicine, New York, NY, ⁸School of Medicine, University of Leeds, Leeds, United Kingdom
Background/Purpose: The Psoriasis Epidemiology Screening Tool (PEST) is a 5-item questionnaire developed to help identify psoriatic arthritis (PsA) at an early stage, with a score…
Abstract Number: 2532 • 2017 ACR/ARHP Annual Meeting
The Relationship between the Degree of Skin Involvement and Joint Activity in Patients with Psa: Experience from the Corrona Registry
Philip J Mease¹, Carol J. Etzel², Jeffrey Lisse³, April W Armstrong⁴, William J Huster³, Sabrina Rebello², Rhiannon Dodge², Talia M Muram³, Sarah Al Sawah³, Mwangi J Murage³, Jeffrey D Greenberg² and William Malatestinic³, ¹Department of Rheumatology, Swedish Medical Center and University of Washington, Seattle, WA, ²Corrona, LLC, Southborough, MA, ³Eli Lilly and Company, Indianapolis, IN, ⁴Keck School of Medicine, University of Southern California, Los Angeles, CA
Background/Purpose: Prior studies have shown an inconsistent relationship between skin and joint symptoms in patients with comorbid PsO and PsA1-3. The objective of the…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].